Tweaking host immune responses for novel therapeutic approaches against Mycobacterium tuberculosis

Agnivesh, Puja Kumari; Sau, Shashikanta; Kumar, Sunil; Kalia, Nitin Pal

doi:10.1016/j.drudis.2023.103693

Cited by 7 publications

(1 citation statement)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among polymers, biocompatible PLGA has found profound use in the fabrication of controlled ATD delivery systems because of the ease in achieving the desired dose and release kinetics by modification of the lactide to glycolide ratio, molecular weight, and drug concentration [250][251][252]. With regard to tissue-resident macrophage targeting for the delivery of ATDs, the surface of the drug carrier is functionalized with ligands, including mannosylated molecule, β-glucan, curdlan (β-1,3 glucose), folic acid, hyaluronic acid, tuftsin peptide, and phosphoserine conjugate, that can be recognized by corresponding receptors on macrophages, such as mannosyl receptor (CD206), dectin-1 receptor, folate receptor, tuftsin receptor, hyaluronic acid receptor, fucosyl and scavenger receptor, Fc receptor, transferrin receptor, formyl peptide receptor (FPR), and other lectin-like receptors [30,253,254] represented in Fig. 7.…”

Section: Targeted Therapymentioning

confidence: 99%

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair,

Greeny,

Nandan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. Graphical Abstract

show abstract